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Abstract 
 
During the past decade, distributed ledger 
technology (DLT) has found its way into application 
areas outside finance, such as supply chain 
management, the Internet of Things, or health care. To 
this end, this novel technology phenomenon has recently 
also caught the attention of researchers and 
practitioners in genomics. Although various DLT-based 
data markets for genome data already exist or are in 
development, the potential of DLT in this context is far 
from exhausted, whereas the possible risks related to the 
application of DLT in genomics are not yet sufficiently 
known. In this work, we investigate the potential 
opportunities and challenges for the application of DLT 
in the field of genomics. Thus, we make an important 
contribution to the safe and socially acceptable use of 
DLT in this unique and highly relevant use context. 
 
 
1. Introduction  
 
Distributed Ledger Technology (DLT) is one of the 
most hyped information technology innovations of the 
last decade that is probably best known for the 
cryptocurrency Bitcoin and its underlying DLT concept 
Blockchain [1]. Yet, the hype around DLT nowadays 
extends far beyond applications in the financial sector, 
with potential benefits of DLT being discussed in 
diverse industries and application scenarios, including 
supply chain management, the Internet of Things, and 
especially health care [2]. Often cited benefits of DLT 
pertain to enabling secure transactions between 
untrustworthy parties through automated, algorithm-
based consensus building mechanisms, which eliminate 
the need for third-party trust enforcement [1], high 
availability of DLT-based systems [3], or the ability to 
automate and enforce processes by means of smart 
contracts [4].  
Recently, DLT has also caught the interest of 
practitioners and researchers within the field of 
genomics [4-6]. Thereby, the diffusion of DLT in 
genomics is currently mainly driven by a small but 
rapidly increasing number of businesses such as Nebula 
Genomics, EncrypGen, or LunaDNA (see section 2.2 
for a more detailed overview of DLT genomics 
businesses). In most cases, the objective of these 
businesses is to operate data markets, where users can 
share their genome data with third parties in exchange 
for tokens. Accordingly, DLT quickly gained the 
interest of the genomics community, as it promises to 
facilitate the exchange of genomic data and offers 
opportunities to reward data providers (e.g. through the 
use of tokens). However, to date, the majority of these 
initiatives is still in a pre-market phase. Furthermore, 
and despite the promising potential of DLT, applications 
of DLT have so far only been successfully implemented 
and operated in a limited number of cases. For example, 
only 8% of the DLT-related projects on GitHub are 
actively maintained [7]. 
Researchers within the field of genomics and 
associated disciplines have only recently begun to 
investigate the full potential of DLT for the genomics 
research community and other relevant stakeholders in 
genomics (e.g., genome data donors, medical 
professionals, pharma industry) [4, 6]. Due to the 
novelty of DLT for the genomics community, we still 
lack a profound understanding of what specific 
opportunities the application of DLT can bring forth for 
genomics, beyond the mere creation of genome data 
markets. Even more so, extant literature and, 
unsurprisingly, also white papers of involved businesses 
paint a rather positive picture of the prospective 
opportunities for DLT in genomics. To this end, the 
potential challenges that the application of DLT in 
genomics can bring forth are barely considered in the 
ongoing discussions about the utility of DLT for the 
genomics community. Overall, we as a community still 
lack knowledge on what are the most promising 
related to the application of DLT in genomics. We 
therefore ask the following research questions: 
 
RQ1: What are opportunities and challenges for the 
application of DLT in genomics? 
RQ2: What is the relative importance of the identified 
opportunities and challenges? 
 
To answer our research questions, we conduct a 
ranking-type Delphi study with an international panel of 
experts on genomics and/or DLT and augment the 
results of the Delphi process with insights from a review 
of white papers and scientific publications on DLT in 
genomics. In doing so, the opportunities and challenges 
for the application of DLT in genomics that are 
described in this work present an important contribution 
to research and practice as they lay the foundation for 
directing adoption efforts towards the most promising 
opportunities as well as the most demanding challenges.  
The remainder of this paper is structured as follows. 
In section two, we provide a brief introduction to DLT 
and an overview of the current state concerning the 
application of DLT in genomics. In section three, we 
detail on our research approach, including panel 
selection and the employed ranking-type Delphi 
method. Section four presents our results in terms of 
identified opportunities and challenges as well as their 
relative rankings, before we discuss our results in 
section five. We conclude the paper in section six. 
 
2. Related research 
 
2.1 Distributed Ledger Technology 
 
DLT is an emerging technology that enables the 
operation of a distributed ledger, which is a special type 
of an append-only, distributed database that is 
particularly suited to the peculiarities of an 
untrustworthy environment [8, 9]. Inherent to DLT is 
the creation of a ledger that is replicated in a network of 
storage devices, which are referred to as nodes. 
Compared to traditional distributed databases, such 
structure allows for the presence of Byzantine failures. 
Byzantine failures include the presence of crashed or 
unreachable nodes, network delays, or malicious 
behavior of nodes [8]. In DLT, new data is added to the 
ledger using transactions that are committed on each 
node’s replication [e.g., 10]. The data is then stored in a 
well-defined structure. Through the use of 
cryptographic techniques (e.g., hashing), data stored in 
the distributed ledger can hardly be removed or 
modified, resulting in near immutability. Each DLT 
design (e.g., Bitcoin [10]) employs a consensus 
mechanism to reach consistency between the 
replications stored on nodes of the distributed ledger. A 
consensus mechanism is an algorithm used to negotiate 
the valid state between nodes of the distributed ledger. 
Consensus mechanisms employ trust models, which 
consider threats and uncertainties in the process of 
consensus finding (e.g., Byzantine failures [8]). DLT 
can be employed to operate a distributed infrastructure 
across multiple parties, who can develop applications on 
DLT. Such applications on DLT make use of so-called 
smart contracts. Smart contracts are computer programs, 
which contain formalized business processes (e.g., 
conditional withdrawals) and are deployed and executed 
on a distributed ledger [e.g., 11]. Smart contracts can 
also retrieve data from the respective distributed ledger 
itself (on-chain) or from the external world (off-chain). 
Off-chain data feeds, which can be called by a smart 
contract to retrieve data are called oracles. 
 
2.2. Distributed Ledger Technology in 
genomics 
 
Genomics is the scientific discipline concerned with 
the sequencing, mapping, and analysis of genomes [12]. 
It is an integral part of contemporary (bio-)medical 
research and the ongoing shift towards a precision 
medicine treatment paradigm in health care [13]. 
Following the completion of the Human Genome 
Project, advances in genome sequencing, mapping, and 
analysis technologies have led to plummeting costs for 
the acquisition of genome data, from costs of around 
USD 95 million per whole genome sequence in 2001 to 
costs of around USD 1,300 per whole genome sequence 
today [14]. However, with the availability of relatively 
inexpensive means for acquiring and analyzing genome 
data on the one hand and the inherent characteristics of 
genome data (e.g., uniqueness, kinship, staticity) on the 
other hand [15], a variety of ethical, legal, and social 
challenges have emerged [16, 17]. Such challenges 
include, for example, trade-offs between individuals’ 
right to privacy and the overall benefit of freely sharing 
genome data [16], interdependent privacy due to kinship 
[18], individuals’ ability to comprehend and interpret 
the results of genetic testing [19], or the handling of 
inadvertent findings [20].  
Employing DLT within genomics promises to 
address many of the aforementioned ethical, legal, 
social challenges [4, 6]. However, since the application 
of DLT in genomics is still in its infancy, DLT’s 
diffusion within the community is currently to a large 
degree driven by a small but rapidly increasing number 
of young businesses. One of the pioneering and most 
prominent businesses in this area being Nebula 
Genomics. Like most players in the commercial DLT-
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in-genomics space, Nebula Genomics aims to offer 
direct-to-consumer genetic testing services, while at the 
same time creating a genome data market where the very 
same consumers can trade their genome data with 
interested third-parties (e.g., researchers, 
pharmaceutical companies) in exchange for tokens of 
Nebula Genomics’ own crypto currency [21]. Similarly, 
EncrypGen, Gene Blockchain, Genomes.io, Shivom, 
and Zenome are also operating or planning to operate 
their own DLT-based genome data market together with 
their own cryptocurrency. A notable exception to the 
aforementioned businesses is Genecoin. Compared to 
the majority of businesses whose aim is to build DLT-
based genome data markets, Genecoin aims at creating 
a permanent storage for individuals’ DNA by storing 
their genome data in the Bitcoin network. Instead of 
giving out a Genecoin cryptocurrency, consumers are 
encouraged to create their own personal cryptocurrency 
off of their Bitcoin seed. Table 1 provides a non-
exhaustive summary of the main players in the 
commercial DLT-in-genomics space. 
Looking at scientific literature related to the 
application of DLT in genomics, we see that this stream 
of research is in a state of emergence (see Table 2). 
While an increasing number of research articles on DLT 
in health care is published, some of which also address 
the case of genomics [e.g., 22, 23, 24], we are aware of 
only four publications that explicitly focus on the 
peculiarities of bringing DLT into genomics. The 
viewpoint articles of Ozercan, et al. [6] and Shabani [4] 
and Thiebes, et al. [25] all provide a general discussion 
of potential that DLT holds for the genomics 
community. In addition, Ozercan, et al. [6] also describe 
the prototype of a DLT-based research infrastructure for 
genomics, called Coinami. In this infrastructure, 
research institutes may place genomics-related research 
jobs (e.g., genome sequence alignment) on the 
distributed ledger, which are then executed by nodes 
(so-called miners) that are rewarded with tokens via a 
coinbase transaction in return. Lee, et al. [5] on the other 
hand develop a DLT-based lossless compression 
platform for genome data. Here DLT is used as a means 
for handling data exchange requests. Interestingly, 
although a variety of different DLT-concepts exists 
(e.g., Blockchain, TDAG, BlockDAG), current 
discourses in research and practice on the application of 
DLT in genomics center around Blockchain only. 
 
3. Methods 
 
In order to identify salient opportunities and 
challenges related to the application of DLT in 
genomics, as well as their relative importance, we 
conduct a ranking-type Delphi study. We provide details 
on the Delphi panel selection and each of the three 
Delphi phases below.  
 
3.1. Panel selection 
 
Delphi studies typically rely in the input of experts 
with profound knowledge on the phenomenon under 
consideration (here DLT in genomics) [26]. Towards 
this end, we identified three groups of experts that could 
aid in the identification of challenges and opportunities 
for the application of DLT in genomics: (1) experts on 
DLT with at least basic knowledge on genomics; (2) 
experts on genomics with at least basic knowledge on 
DLT; and (3) individuals with high expertise in both, 
DLT and genomics.  
Literature provides thresholds of 7 to 30 
knowledgeable experts that are necessary to generate 
meaningful insights using Delphi [27]. To recruit an 
adequate number of experts from the three relevant 
groups, we employed a purposeful sampling strategy 
[28] and used different techniques to contact potential 
participants. First, we contacted the founders and 
employees (whom we assumed to have the required 
expertise) of the several DLT-in-genomics businesses 
Table 1. Excerpt of DLT genomics businesses. 
DLT Genomics Business Objective 
EncrypGen 
(https://encrypgen.com/) 
DLT-based genome data market 
Gene Blockchain 
(http://www.geneblockchain.org) 
DLT-based genome data market 
Genecoin  
(http://genecoin.me/) 
Permanent storage of one’s 
DNA using Bitcoin 
Genomes.io (https://genomes.io/) DLT-based genome data market 
Nebula Genomics 
(https://nebula.org/) 
DLT-based genome data market 
Shivom (https://www.shivom.io/) DLT-based genome data market 
Zenome 
(https://zenome.io/about/) 
DLT-based genome data market 
 
Table 2. Literature on DLT in genomics. 
Article Type Research Focus 
Lee, et al. [5] Original 
article 
Development of DLT-based lossless 
compression platform for genome data 
Mackey, et al. 
[22] 
Viewpoint Challenges and opportunities for DLT in 
health care (genome data discussed as an 
example) 
Roman-
Belmonte, et 
al. [23] 
Viewpoint Discussion of the transformatory 
potential of DLT for health care (genome 
data discussed as an example) 
Ozercan, et al. 
[6] 
Viewpoint Discussion of the transformatory 
potential of DLT for genomics / proposal 
of a DLS for genomics 
Shabani [4] Viewpoint Discussion of the transformatory 
potential of DLT for genomics 
Talukder, et 
al. [24] 
Original 
article 
Development of a consensus protocol for 
DLT-based electronic health records 
(genome data discussed as an example) 
Thiebes, et al.  Viewpoint Discussion of the transformatory 
potential of DLT for genomics 
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(see Table 1) via email, contact forms on their websites, 
and social networks. We also reached out to authors of 
white papers on this topic (many of which overlapped 
with the founders and employees of the previously 
named startups), researchers who had previously 
published articles on DLT genomics (see Table 2), and 
industry and international research consortia (i.e. The 
Global Alliance for Genomics and Health, and 
FORCE11). Lastly, we used personal contacts to 
researchers of whom we knew had some relevant 
experience and snowballing to recruit additional 
experts. Overall, this sampling strategy resulted in 12 
actual participants for the brainstorming phase. Table 
A1 in the appendix provides and overview of relevant 
demographics for these participants. 
 
3.2. Data collection and analysis methods 
 
We conducted the entire study over the Internet by 
means of an online survey software for the questionnaire 
rounds and email to communicate with our participants 
after the brainstorming phase. 
 
3.2.1. Brainstorming phase. At the beginning of the 
brainstorming phase we introduced participants to the 
Delphi procedure as well as to DLT and genomics in 
order to establish a common understanding for both 
concepts. Drawing on previous ranking-type Delphi 
studies [16, 26], we next asked participants to name and 
briefly describe three to ten opportunities and challenges 
for the application of DLT in genomics. We also gave 
participants the possibility to proceed with the 
questionnaire in case they did not want to provide three 
opportunities or challenges (e.g., some participants were 
only able to name one opportunity but multiple 
challenges, or vice versa). At the end of the 
brainstorming questionnaire we asked participants to 
provide basic demographic information and an email 
address so that we could invite them for the subsequent 
Delphi phases. 
Overall, participants provided us with 33 entries for 
potential opportunities and 39 entries for potential 
challenges. We consolidated the set of responses by 
manually aggregating duplicate responses, unifying 
terminology, and grouping similar opportunities/ 
challenges [27, 29]. In order to augment the lists of 
opportunities and challenges, we further conducted a 
review of related literature and white papers. To identify 
scientific publications addressing the use of DLT in 
genomics, we searched pertinent scientific databases 
that cover a wide range of journals and conferences: 
ACM Digital Library, EBSCOhost, IEEE Xplore, 
ProQuest, ScienceDirect, and PubMed. We searched 
each database with the following string in title, abstracts 
and keywords: (“distributed ledger technolog*” OR 
“blockchain*” OR “DLT”) AND (“genom*” OR 
“genetic*” OR “DNA” OR “proteonomic*”) and 
limited our search to peer-reviewed articles to ensure 
high quality of articles. Our search yielded 573 articles, 
of which we deemed only five relevant for this research. 
We also included eight available white papers of 
relevant businesses. Subsequently, two researchers 
coded potential opportunities and challenges in these 
articles and white papers independently and compared 
their results. 
The data consolidation process and literature review 
resulted in a list of 17 opportunities and 15 challenges 
for the application of DLT in genomics. In order to 
ensure that participants’ thoughts were adequately 
captured and represented in the consolidated list, we 
asked participants to approve the list of opportunities/ 
challenges as suggested by Paré, et al. [27]. Participants’ 
feedback led to minor adjustments, (e.g., rephrasing 
certain aspects), but did not result in adding new or 
removing existing opportunities/challenges. 
 
3.2.2. Narrowing down and ranking phases. Extant 
literature suggests 20 or less items for the ranking phase 
[29], since a large number of items reduces participants 
ability to properly distinguish the ranks of individual 
items [30]. The brainstorming phase yielded less than 20 
opportunities as well as less than 20 challenges. Thus, 
and in an attempt to reduce panel attrition, we decided 
to skip the narrowing down phase and directly proceed 
to the ranking phase, although the narrowing down 
phase might in some cases provide additional insights.  
In the ranking phase, we presented the 17 
opportunities and 15 challenges in random order and 
asked participants to rank them according to the 
following rationales: For the opportunities, we asked 
participants to rank them with regard to their value for 
the genomics community from highest to lowest. For the 
challenges, we asked participants to rank them with 
respect to which challenges deserve the genomics 
community’s attention and resources from most to least. 
Participants were also asked to justify their rankings, 
although this was not mandatory and could be skipped. 
We used Kendall’s coefficient of concordance (W) to 
measure the degree of consensus between the experts’ 
rankings (Paré et al. 2013; Schmidt 1997; Singh et al. 
2009). It attains values between 0 and 1, whereby 
consensus is considered strong for W ≥ 0.7, moderate 
for 0.7 > W ≥ 0.5, and weak for 0.5 > W ≥ 0.3 (Schmidt 
1997). For lower values no consensus is presumed. 
Moreover, a Friedman test was used to calculate the 
mean rank for each opportunity/challenge (Friedman 
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1937). Nine participants signaled their willingness to 
participate in additional Delphi rounds after the 
brainstorming phase, with only 3 actually completing 
the ranking phase by the time of writing this paper. 
 
4. Results 
 
Based on the inputs of experts during the Delphi 
study and our literature review, we were able to identify 
17 opportunities (see Tab. 3) and 15 challenges (see 
Tab. 4) for the application of DLT in genomics. In order 
to structure identified opportunities and challenges, we 
drew on the TOE-framework [31] and categorized 
opportunities and challenges into technology (i.e., 
opportunities/challenges related to the technology 
itself), organization (i.e., opportunities and challenges 
related to organizational structures of the genomics 
community), and environment (opportunities and 
challenges related to factors that are external to the 
genomics community). 
 
4.1. Opportunities for DLT in genomics  
 
4.1.1. Technology. Most identified opportunities (9 out 
of 17) belong to the technology category. Owing to the 
inherent characteristics of genome data and their high 
sensitivity, protection of genetic privacy is a major 
objective in genomics. Consequently, we identified 
several technological opportunities for DLT in 
genomics that support the protection of data owners’ 
genetic privacy. DLT, for example, warrants high 
degrees of confidentiality by ensuring that genome data 
is only disclosed to third parties with consent of the data 
owner. Likewise, and completing the so-called CIA 
triad, DLT also warrants high degrees of integrity by 
ensuring that genome data is not altered without data 
owners’ prior agreement, as well as high degrees of 
availability of DLT-based platforms and services (and 
thus genome data) due to being inherently decentralized 
and removing single points of failure. On the one hand 
DLT further enables data owners to maintain their 
genome data anonymously, meaning that the tracing of 
data owners’ real identities requires a prohibitive 
amount of effort, while on the other hand also affording 
high levels of transparency by ensuring the traceability 
of all actions performed on the data. From the 
perspective of data users (e.g., researchers, medical 
professionals, insurers) the durability as well as the 
accuracy of genome data records are important factors 
for an effective use of such data. Towards this end DLT 
affords the establishment of a permanent genome data 
record (opportunity: durability), as well as verifying the 
correctness of genome data (opportunity: data 
accuracy). Adding to this, DLT-based systems reduce 
storage requirements for those in charge of governing 
the genome data by enabling their distributed storage. 
Finally, many contemporary DLT concepts rely on 
compute intensive tasks as part of their consensus 
protocols (e.g., proof-of-work). DLT therefore might 
allow for the solving of compute intensive tasks in 
genomics by enabling the distribution of compute tasks 
to nodes of a DLT network, for example, as part of the 
proof-of-work principle. 
 
4.1.2. Organization. We categorized 7 out of the 17 
opportunities into the organization category. Based on 
its distributed and decentralized nature, DLT eliminates 
the need for central authorities. Thus, it supports 
decentralization within the genomics community by, for 
example, helping to break up extant data silos or 
affording the removal of (costly) intermediaries. While 
the current genomics ecosystem is relatively closed with 
several large closed-access databases and limited 
possibilities for individuals to actively participate, the 
openness of DLT (i.e., many DLT-based systems are 
open to everyone) promotes the active participation of 
all stakeholders (e.g., researchers, data owners) in the 
generation, sharing, and processing of genome data. 
Another frequent problem within genomics pertains to 
heterogeneity of different information systems, which 
often hinders effective exchange of genome data 
between different entities. DLT supports 
interoperability by facilitating the standardization of 
technologies and policies. Similarly, many processes in 
genomics (especially the granting and revocation of 
consents) are complex and tedious. DLT supports the 
formalization and subsequently automatic execution of 
processes in genomics through the utilization of smart 
contracts. An often-raised question about genome data 
relates to the ownership of the data. To this end, DLT 
not only allows to enforce property rights over personal 
genome data by enabling the verification and 
administration of said property rights, but also gives 
data owners direct control over their data, by enabling 
data owners to grant and revoke access rights to their 
genome data flexibly and on-demand, based on their 
changing data sharing and access preferences. Closely 
related to the question of ownership is the question of 
how to reimburse entities for the disclosure or 
processing of genome data. Thereby, application of 
DLT in genomics allows for the creation of a token 
economy, which enables the exchanging of value in the 
form of tokens (e.g., monetary value, access to services) 
for the disclosure and/or processing of genome data. 
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4.1.3. Environment. Finally, one opportunity belongs 
to the environment category. Kinship is a central 
characteristic of genome data, meaning that blood 
relatives share certain genetic traits with each other [15]. 
This could potentially also impede the privacy of blood 
relatives when sharing one’s genome data. DLT 
supports the preservation of such interdependent 
privacy by requiring that affected relatives approve of 
one sharing their genome data prior to the actual 
sharing. 
 
4.2. Challenges for DLT in genomics  
 
4.2.1. Technology. Similar to the opportunities, the 
majority of challenges (7 out of 15) belong to the 
technology category. Although DLT receives 
tremendous attention from research and practice it is 
still a relatively immature technology with many 
unresolved questions and issues. Especially in terms of 
security and the sensitivity of genome data, technology 
maturity or more precisely the lack thereof remains an 
issue. Adding to this, data handling (i.e., the retrieval 
and management of genome data) and data storage are 
two challenges deeply rooted in DLT characteristics. 
Most DLT-concepts were designed for small 
transactional data and are unable to store genomics-
sized data sets on ledger [4, 6]. Furthermore, current 
implementations of DLT lack the capabilities to 
efficiently query genome data (e.g., accessing arbitrary 
parts of a dataset or streaming data). Towards this end, 
many extant proposals for DLT-based platforms in 
genomics are also based on Blockchain, whose primary 
consensus protocols are based on proof-of-work, which 
relies on compute-intensive tasks. Although other less 
resource-consuming consensus mechanisms (e.g., 
proof-of-stake) have been proposed, the dominance of 
inefficient consensus protocols wastes precious 
computing resources that could be used for solving 
genomics-related problems instead. As pointed out 
before, ensuring integrity of data is an often-cited 
opportunity of DLT. However, at the same time DLT’s 
rigidness could also pose a serious challenge in terms of 
integrity, namely if those rightfully interested in 
changing data are being hindered to do so (e.g., due to 
prohibitively expensive consensus mechanisms or 
simply a lost encryption key). 
Similar to integrity, durability was not only 
identified as an opportunity but also as a challenge. Due 
to rigidness of DLT-based systems and data replication, 
Table 3. Opportunities for DLT in genomics. 
Cat. Opportunity Src 
Te
ch
no
lo
gy
 
Anonymity. DLT enables data owners to maintain (e.g., store, share) their (genome) data without their real identities being traceable 
since it is either not possible or requires unreasonable efforts. ● 
Availability. DLT increases the probability to which a DLT-based (genome) data platform or service can be reached in a fully 
functioning condition, due to it being a decentralized system. ● 
Confidentiality. DLT is capable of ensuring that (genome) data is only disclosed to third parties with consent of the data owner, where 
the data owner defines the granularity and form of the (genome) data. ● 
Data accuracy. DLT allows to verify the correctness of (genome) data. ● 
Data storage. DLT reduces data storage requirements for individual data owners by enabling the distributed storage of (genome) data. ◑ 
Distributed computing. DLT allows the solving of compute-intensive problems by enabling the distribution of compute tasks to nodes 
of a DLT network (e.g., as part of proof-of-work). ◑ 
Durability. DLT affords the establishment of a permanent (genome) data record. ● 
Integrity. DLT is capable of ensuring that (genome) data is not altered without prior agreement of the data owners. ● 
Transparency. DLT affords the traceability of the handling of (genome) data (e.g., data access, data processing, data search) by means 
of logging all performed actions. ● 
O
rg
an
iz
at
io
n 
Decentralization. DLT eliminates the need for central authorities, thus helping to break up data silos and affording the removal of 
intermediaries. ● 
Flexibility. DLT enables the on-demand granting and revocation of access rights to (genome) data based on data owners' changing data 
sharing and access preferences. ● 
Interoperability. DLT supports the exchange of (genome) data among different information systems by means of facilitating 
standardization of technologies and policies. ◑ 
Openness. DLT promotes the active participation of all stakeholders (e.g., researchers, data owners) in the generation, sharing, and 
processing of (genome) data. ● 
Ownership. DLT allows for the verification and administration of property rights on personal (genomic) data. ◑ 
Process automation. DLT affords the formalization of processes in genomics through smart contracts for the purpose of automating 
these processes. ● 
Token economy. DLT enables the exchanging of value via of tokens (e.g., monetary value, access to services) for the disclosure and/or 
processing of (genome) data. ● 
En
v.
 Interdependent privacy. DLT allows to enforce that relatives approve of a data owner sharing their genome data by means of smart 
contracts. ◐ 
Column Source: ◐ = opportunity originated from brainstorming phase only; ◑ = opportunity originated from literature review only; ● = 
opportunity originated from brainstorming phase and review 
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completely removing information that has once been 
stored from the system is difficult and, in many cases, 
impractical. Another often cited opportunity for the 
application of DLT in genomics is transparency. Yet, 
such uncompromising transparency could also impede 
individuals’ privacy by providing information or 
enabling the deduction of information that one does not 
wish to be available to others (e.g., logs of an individual 
sharing their genome data with a cancer research center 
could indicate that this person suffers from cancer). 
 
4.2.2. Organization. We categorized five challenges as 
organizational challenges. While we identified 
technology maturity as a technology-related challenge, 
novelty of DLT also poses a challenge to the genomics 
community itself as its benefits and risks are largely 
unknown or at least poorly understood. Not only might 
this lead to ineffective implementations but also to 
outright rejection of this technology. Likewise, getting, 
maintaining, and managing access to DLT-based 
systems still requires comparably much effort. Overall, 
most DLT-based systems still suffer from poor ease of 
use, which could also hinder adoption within the 
genomics community. The effective application of DLT 
within genomics requires interoperability between a 
multitude of diverse information systems. Although 
DLT could facilitate standardization of technologies and 
policies within genomics, the current situation is far 
from this ideal, essentially creating a chicken-and-egg 
problem in terms of interoperability. Adding to this, 
effective application of DLT also requires the 
formalization of certain aspects (e.g., access 
requirements). Here, different stakeholders might have 
conflicting interests, which could be difficult or 
impossible to resolve. From an ethical point of view, 
rewarding data owners with tokens for sharing their 
genome data might result in mindless data sharing. Due 
to the unique characteristics of genome data, future uses 
and potential avenues for privacy infringements are 
difficult to foresee, even for professionals. Introducing 
monetary incentives into this ecosystem could 
encourage data sharing without being able to adequately 
assess the potential issues.  
 
4.2.3. Environment. Lastly, the environment category 
comprises three challenges. A frequent requirement 
within health information technology is a so-called 
emergency access, where in cases of emergency medical 
professionals are granted access to patient data without 
their prior consent. Such access might violate 
fundamental principles of DLT and could be impossible 
or at least be highly difficult to realize. Next, openness 
refers to the system promoting the active participation 
of involved stakeholders. However, at the same time 
such an open system design could also invite malicious 
users into the system and result in new attack vectors or 
the misuse of the system and especially stored genome 
data. The third and last challenge in this category refers 
to uncertain regulation. Since DLT is a relatively young 
technology its true benefits as well as its problems for 
societies around the globe are largely unknown. In an 
attempt to keep up with the rapid technological 
advances, regulation in different parts of the world is 
constantly changing and adapting to the new 
technological realities. Consequently, changes in 
Table 4. Challenges for DLT in genomics. 
Cat. Challenge Src 
Te
ch
no
lo
gy
 
Data handling. DLT-based systems are not designed to retrieve or manage high volumes of (genome) data efficiently. ● 
Data storage. DLT-based systems are not designed to store genomics-size data sets on-ledger. ● 
Durability. Disclosing (genome) data via DLT is a permanent, difficult-to-reverse decision. ● 
Efficiency. Consensus mechanisms in DLT-based systems such as proof-of-work waste computing resources. ◑ 
Integrity. Altering (genome) data that is stored, shared, or managed via DLT-based systems might require much effort or be impossible. ● 
Technology maturity. DLT is an immature technology with potential security issues. ● 
Transparency. Transparency of distributed ledger systems might impede individuals' privacy. ● 
O
rg
an
iz
at
io
n Conflicting interests. Different stakeholders might have conflicting interests, which are impossible to resolve. ● 
Ease of use. Getting, maintaining, and managing access to (genome) data via DLT requires much effort. ● 
Interoperability. Effective use of DLT for genomics requires interoperability between a multitude of diverse information systems. ● 
Novelty. DLT is largely unknown to the genomics community and poorly understood. ● 
Token economy. Rewarding data owners with tokens for sharing their (genome) data can incentivize mindless data sharing. ◐ 
En
v.
 
Emergency access. Situations that require access to health-related data by third parties without data owners' prior approval (e.g., by 
medical professionals in an emergency, when data owners are unconscious), might violate foundational principles of DLT.  
◑ 
Openness. Openness of DLT-based systems can result in new attack vectors and misuse of the system and stored (genome) data.  ● 
Uncertain regulation. Regulations around DLT and genetic privacy are constantly changing and evolving differently in different parts 
of the world. 
● 
Column Source: ◐ = challenge originated from brainstorming phase only; ◑ = challenge originated from literature review only;  
● = challenge originated from brainstorming phase and review 
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regulation around the world could render certain 
applications of DLT illegal or impossible. 
 
4.3. Ranking of opportunities and challenges 
 
Based on the inputs we received from our panel so far, 
the top three opportunities are (1) confidentiality, (2) 
ownership, and (3) flexibility, whereas the top three 
challenges are (1) uncertain regulation, (2) durability, 
and (3) ease of use. Although Kendall’s W must be 
considered low for both rankings (WOpportunities = 0.346, 
WChallenges = 0.450), overall consensus seems to be 
higher for the challenges ranking. Table 5 shows the 
mean ranks as well as the resulting overall ranks of the 
first round for all elicited opportunities and challenges. 
 
5. Discussion  
 
5.1. Principal findings 
 
The objective of this research was to identify salient 
opportunities and challenges for the application of DLT 
in genomics. To this end, we conducted a ranking-type 
Delphi study with an international panel of experts and 
augmented the results of the brainstorming phase with a 
comprehensive literature review, which altogether 
yielded 17 diverse opportunities as well as 15 diverse 
challenges for the application of DLT in genomics. 
Consistent with current efforts on DLT in genomics, our 
Delphi study and literature review yielded token 
economy as one potential opportunity. However, 
contrary to the currently predominant focus on the use 
of DLT to establish genome data markets, results of our 
Delphi study also yielded several opportunities deemed 
more important than the creation of a token economy 
(e.g., confidentiality, ownership, or flexibility). 
Furthermore, uncertain regulation was by far deemed as 
the most important challenge, which is also consistent 
current debates around the application of DLT in critical 
contexts such as health care or finance. Since DLT has 
received tremendous attention from researchers and 
practitioners in the health care sector [23], an obvious 
question is whether the opportunities and challenges 
presented here are unique to genomics. While many of 
the opportunities and challenges certainly also apply to 
health care in general, we also see some opportunities 
(e.g., interdependent privacy) and challenges (e.g., data 
handling and data storage) that are unique or at least 
more relevant to the genomics context. Moreover, the 
relative rankings of individual opportunities and 
challenges might be different for the genomics context 
than for a general health care context. 
Interestingly, many of the identified opportunities 
were at the same time also named as a potential 
challenge. A prime example for this is transparency, 
which overall might be an opportunity for the genomics 
community but could at the same time also infringe 
individuals’ privacy. We think that there are two 
potential reasons for this that can also be found in the 
presented challenges. First, DLT is a novel and still 
poorly understood phenomenon in the genomics 
community. With time and increasing knowledge about 
DLT, we might be able to address several challenges, 
transforming them into pure opportunities. Second, 
many of the conflicting interests between the diverse 
stakeholders involved in genomics might be 
unresolvable, creating a reality in which the very same 
DLT characteristic is an opportunity for some 
stakeholders, while being a challenge to others. 
Looking at the sources of identified opportunities 
and challenges, we see that most opportunities (12 out 
of 17) as well as most challenges (12 out of 15) were 
actually named in both, the brainstorming phase of our 
Delphi study and in extant literature. Although this 
surprising finding seemingly contradicts our initial 
statement that current discussions about DLT in 
Table 5. First round rankings. 
Opportunity Mean rank Overall rank 
Confidentiality 4.00 1 
Ownership 4.33 2 
Flexibility 5.67 3 
Decentralization 6.33 4 
Openness 6.67 5 
Interdependent privacy 7.00 6 
Anonymity 7.67 7 
Transparency 9.00 8 
Durability 9.67 9 
Interoperability 10.00 10 
Availability 10.33 11 
Integrity 10.67 12 
Data accuracy 11.33 13 
Distributed computing 11.67 14 
Token economy 12.33 15 
Process automation 12.67 16 
Data storage 13.67 17 
 Kendall’s W = 0.346 
Challenge Mean rank Overall rank 
Uncertain regulation 1.33 1 
Durability 5.67 2 
Ease of use 6.00 3 
Emergency access 6.00 3 
Novelty 6.00 3 
Technology maturity 6.00 3 
Openness 6.33 7 
Efficiency 8.67 8 
Integrity 9.33 9 
Interoperability 9.67 10 
Token economy 10.00 11 
Data storage 10.33 12 
Transparency 10.33 12 
Conflicting interests 11.00 14 
Data handling 13.33 15 
 Kendall’s W = 0.450 
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genomics are predominantly positive, it must be noted 
that potential challenges were often only named 
implicitly. Moreover, sections discussing potential 
challenges were rather short and often downplayed 
named challenges. 
 
5.2. Implications 
 
Our work has several implications for research and 
practice. For practitioners, including those researchers 
enticed by the utilization of DLT for their work, our 
research highlights several benefits brought forward by 
the application of DLT. It especially shows that there are 
many benefits of DLT beyond the creation of mere data 
markets. However, our results also show the presence of 
a diverse set of challenges that need to be overcome in 
order to realize the full potential of DLT in genomics. 
Those interested in the utilization of DLT in genomics 
should therefore develop strategies to address the most 
pressing challenges.  
For research, we are among the very first to 
systematically elicit opportunities and especially 
challenges for the nascent phenomenon that is DLT in 
genomics, as well as their relative importance. We 
thereby add to research a better and contextualized 
understanding of DLT. In particular, we strengthen the 
importance of genomics as a research context for the 
application of DLT that, although similar to the 
application of DLT in general health care, possesses 
some unique features like interdependent privacy issues. 
We also highlight the very existence of the dual roles of 
some opportunities that at the same time are regarded as 
challenges (or vice versa). Starting from here, 
researchers enticed by the application of DLT in 
genomics can use our lists of opportunities and 
challenges to further investigate specific opportunities 
or challenges. The dual role of some 
opportunities/challenges also warrants further, in-depth 
investigations. 
 
5.3. Limitations and future research 
 
Despite this study being a first step towards a more 
nuanced contemplation of the application of DLT in 
genomics, our research is not without limitations. First, 
the results presented in this study are to a large degree 
based on the inputs of a limited number of experts. This 
is mainly due to the fact that there is a shortage of 
professionals with expertise in DLT and genomics and 
that many experts, especially those working for 
businesses in the DLT-in-genomics space, did not 
respond to our invitations. Although the number of 
experts who participated in our study is within 
established thresholds, we tried to account for this 
limitation by also conducting a comprehensive review 
of related white papers and research articles. We are 
thus confident that our results provide a comprehensive 
picture of the opportunities and challenges for DLT in 
genomics. Another limitation of our work pertains to the 
fact that so far only 3 experts completed the first ranking 
phase, which is why our rankings must be considered 
preliminary at best. Although such high panel attrition 
is not uncommon in Delphi studies, we will continue to 
invite the remaining experts to complete the ranking and 
also investigate other means (e.g., a survey) to establish 
a more robust ranking of the presented opportunities and 
challenges. Towards this end, and drawing on the 
conflicting interests challenge, future research should 
also investigate the potential existence of different 
relative rankings of the presented opportunities and 
challenges for different stakeholders in genomics. 
 
6. Conclusion 
 
Although DLT has recently emerged as a hot topic 
within the genomics community, little is known about 
the actual opportunities and challenges for the 
application of DLT in genomics. Within this research 
we systematically elicited 17 opportunities and 15 
challenges for DLT in genomics as well as their relative 
importance. Thereby, we make important contributions 
to practice and research. For practice, we highlight 
application opportunities for DLT in genomics beyond 
genome data markets as well as important potential 
pitfalls that need to be addressed. For research, we 
underline genomics as a promising application area for 
DLT and support a more nuanced, less hyped view of 
this phenomenon. We also lay the foundations for 
researchers interested in differences between the 
application of DLT in genomics and in health care in 
general. 
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8. Appendix 
 
Table A1. Delphi Panel Characteristics. 
Characteristics Panel profile (n=12) 
Sex Female: 25,00% 
Male: 75,00% 
Age (years) Avg.: 43 
Min.: 29;  Max.: 66 
Nationality U.S.: 25,00% 
German: 16,67% 
Other: 8,33% 
Experience in 
genomics (years) 
Avg.: 7,25 
Min.: 1;  Max.: 25 
Experience in DLT 
(years) 
Avg.: 2,79 
Min.: 0;  Max.: 12 
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